FindTrial
Sign In

Multidimensional Validation of Novel Biomarkers for Organ Injury in Cancer Immunotherapy

Multidimensional Validation of Novel Biomarkers for Organ Injury in Cancer Immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118241
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

ICIs-irAEs Group:None
ICIs-non-irAEs Group:None
Non-ICIs Group:None
Healthy Group:None

Sponsors

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Blood samples are obtainable, and informed consent is signed; 2. Age > 18 years; 3. Cancer patients who have not received immunotherapy; or cancer patients who have received immunotherapy without adverse reactions; or cancer patients who have received immunotherapy with adverse reactions.

Exclusion criteria

Exclusion criteria: 1. Informed consent not obtained.

Design outcomes

Primary

MeasureTime frame
Cardiac function impairment;Lung function impairment;—

Secondary

MeasureTime frame
Liver function impairment;Renal function impairment;Pancreatic function impairment;Impairment of blood function;sepsis;Mortality;—

Countries

China

Contacts

Public ContactZhijun Guo

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

zhijunysh@163.com+86 186 6897 0135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026